Pfizer and Sangamo Therapeutics: Hemophilia A Gene Therapy
In May 2017, Sangamo Therapeutics (SGMO) and Pfizer (PFE) announced a collaboration for hemophilia A gene therapy that includes SB-525, which is one of Sangamo Therapeutics’ four lead product candidates. This collaboration is highly synergistic, as it combines Pfizer’s expertise in rare diseases with Sangamo Therapeutics’ expertise in genomic therapies.